You are here: Industry Insights > AZD7442

News List

Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy prnasia
December 14, 2021
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
AZD7442 reduces COVID-19 risks by 83 percent in Phase III trial EuropeanPharmaceuticalReview
November 26, 2021
AstraZeneca has announced new data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials which both showed robust efficacy from a one-time intramuscular...
New Analyses of Two AZD7442 Covid-19 Trials Confirm Robust Efficacy and Long-Term Prevention in High-Risk Populations AmericanPharmaceuticalReview
November 22, 2021
New data from the AZD7442 COVID-19 PROVENT prevention and TACKLE outpatient treatment Phase III trials both showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
New analyses of two AZD7442 COVID-19 phase-III trials in high-risk populations confirm robust efficacy and long-term prevention ExpressPharma
November 19, 2021
AstraZeneca yesterday said that new data from the AZD7442 COVID-19 Provent prevention and Tackle outpatient treatment phase-III trials showed robust efficacy from a one-time intramuscular (IM) dose of the long-acting antibody (LAAB) combination.
Update on AZD7442 STORM CHASER Trial in Post-Exposure Prevention of Symptomatic COVID-19 drugs
June 29, 2021
AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
STORM CHASER Trial Fails to Meet Primary Endpoint in Post-Exposure Prevention of Symptomatic COVID-19 americanpharmaceuticalreview
June 17, 2021
AstraZeneca announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus.
Agreement builds on an earlier announcement that included support for the clinical development and supply of the treatment worldpharmanews
March 22, 2021
AstraZeneca has modified an existing agreement with the US Government to supply up to 500,000 additional doses of AZD7442, a long-acting antibody (LAAB) combination which is in late-stage development for the prevention and treatment of COVID-19.
AstraZeneca to supply 500,000 additional doses of COVID-19 antibody cocktail to US expresspharma
March 22, 2021
The drugmaker said the $205 million US extension for 500,000 antibody doses builds on a contract agreed with government agencies in October for initial supplies of 200,000 doses of the antibody cocktail, AZD7442.
AstraZeneca to supply 500,000 doses of Covid-19 antibody to the US pharmaceutical-technology
March 18, 2021
AstraZeneca (AZ) has signed an agreement with the US Department of Health and Human Services (HHS) and the Department of Defense (DoD) for the supply of up to 500,000 additional doses of its Covid-19 antibody treatment for $205m.
Trial to assess AstraZeneca’s long-acting COVID-19 antibody therapy europeanpharmaceuticalreview
February 10, 2021
The ACTIV-3 sub-study will evaluate the safety and efficacy of the AZD7442 synthetic antibody combination in at least 150 participants with mild-to-moderate COVID-19.

Previous page 1 2 3 Next page